WHITEHOUSE STATION (dpa-AFX) - Syndax Pharmaceuticals, Inc. and Merck (MRK) announced they have entered into a clinical trial collaboration to evaluate the safety and efficacy of combining Syndax's entinostat, an investigational epigenetic therapy, with Merck's KEYTRUDA (pembrolizumab), the first anti-PD-1 therapy approved in the United States.
The Phase 1b/2 study will evaluate the combination regimen in patients with either advanced non-small cell lung cancer or melanoma. The study is expected to begin enrolling patients in the second half of 2015.
Copyright RTT News/dpa-AFX